A practical reference on storage: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-13. Anything still debated is marked as such rather than presented as settled.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
The author of a 1994 study concluded that it was only in the second half of the 20th century that medical advances have extended the life expectancy of those who live into adulthood. though this is flatly contradicted by 19th- and early 20th-century census and registration data and by estimates for medieval and ancient populations: US and English expectation of remaining years at age 15 for example rose from about 44 in the mid-19th century to 56 by 1950, and has since increased to 65–67; for English landholders (a relatively privileged group) it was 33 years c.1300, while Ulpian's life table for ancient Rome indicates only 30 years. Reliable references to individuals in antiquity who lived past 100 years are quite rare, but they do exist. For instance, Cicero's wife Terentia was reported by Pliny the Elder to have lived from 98 BC to 6 AD, 103 years. Regnal dates of Bronze Age monarchs are notoriously unreliable; the sixth dynasty Egyptian ruler Pepi II is sometimes listed as having lived c. 2278 – c. 2184 BC, as he is said to have reigned for 94 years, but alternative readings cite a reign of just 64 years. Adad-guppi, mother of the last king of the Neo-Babylonian Empire Nabonidus apparently lived from c. 648-544 BC (c. 104 years) according to inscriptions on funeral steles. Zhao Tuo, a Qin Dynasty general, reportedly lived to age 103. Tuoba Liwei also reportedly lived to 103. Marcus Valerius Corvus reportedly lived to 100. Diogenes Laërtius (c.
Treatment typically takes place in hospital such as in a burn unit or intensive care unit. Efforts may include stopping the cause, pain medication, antihistamines, antibiotics, intravenous immunoglobulins or corticosteroids. Together with TEN, SJS affects 1 to 2 people per million per year. Typical onset is under the age of 30. Skin usually regrows over two to three weeks; however, complete recovery can take months. Overall, the risk of death with SJS is 5 to 10%.
== Epidemiology == Corneal transplant is one of the most common transplant procedures. Although approximately 100,000 procedures are performed worldwide each year, some estimates report that 10 million people are affected by various disorders that would benefit from corneal transplantation. In Australia, approximately 2,000 grafts are performed each year. According to the NHS Blood and Transplant, over 2,300 corneal transplant procedures are performed each year in the United Kingdom. In the one-year period ending 31 March 2006, 2,503 people received corneal transplants in the UK.
These names were later suggested for element 114 (flerovium) and element 116 (moscovium). Flerovium became the name of element 114; the final name proposed for element 116 was instead livermorium, with moscovium later being proposed and accepted for element 115 instead. Traditionally, the names of all noble gases end in "-on", with the exception of helium, which was not known to be a noble gas when discovered. The IUPAC guidelines valid at the moment of the discovery approval however required all new elements be named with the ending "-ium", even if they turned out to be halogens (traditionally ending in "-ine") or noble gases (traditionally ending in "-on"). While the provisional name ununoctium followed this convention, a new IUPAC recommendation published in 2016 recommended using the "-on" ending for new group 18 elements, regardless of whether they turn out to have the chemical properties of a noble gas. The scientists involved in the discovery of element 118, as well as those of 117 and 115, held a conference call on 23 March 2016 to decide their names. Element 118 was the last to be decided upon; after Oganessian was asked to leave the call, the remaining scientists unanimously decided to have the element "oganesson" after him. Oganessian was a pioneer in superheavy element research for sixty years reaching back to the field's foundation: his team and his proposed techniques had led directly to the synthesis of elements 107 through 118.
Sources: en.wikipedia.org
== Sequence representation == Following the header line, the actual sequence is represented. Sequences may be protein sequences or nucleic acid sequences, and they can contain gaps or alignment characters (see sequence alignment). Sequences are expected to be represented in the standard IUB/IUPAC amino acid and nucleic acid codes, with these exceptions: lower-case letters are accepted and are mapped into upper-case; a single hyphen or dash can be used to represent a gap character; and in amino acid sequences, U and * are acceptable letters (see below). Numerical digits are not allowed but are used in some databases to indicate the position in the sequence. The nucleic acid codes supported are:
=== Binding assays === Polyhistidine-tagging can be used to detect protein-protein interactions in the same way as a pull-down assay. Polyhistidine tagging has several advantages over other tags commonly used for pull-down assays, including its small size, high binding capacity of the resin, few naturally occurring proteins binding to the carrier matrices and the increased stability of the carrier matrix over monoclonal antibody matrices.
== History == Thyroxine was first isolated in pure form in 1914 at the Mayo Clinic by Edward Calvin Kendall from extracts of hog thyroid glands. The hormone was synthesized in 1927 by British chemists Charles Robert Harington and George Barger.
Sources: en.wikipedia.org
== Function in Disease and Immunity and Clinical Relevance == Reticular cells do far more than support immune cells. They actively shape immune responses during disease and repair. As mentioned previously, their combined role in structure and signaling makes them crucial in both innate and adaptive immunity. Li et al. (2021) explain that fibroblastic reticular cells in lymph nodes organize structure, recruit immune cells, and present antigens. Additionally, it has been shown that they also induce interactions between dendritic cells, macrophages, and lymphocytes. This type of organization performed by the reticular cells ensures that immune reactions occur in the correct sequence, facilitating that a proper response happens. In a pathological environment, reticular cells adapt to regulate inflammation and tissue remodeling. For instance, when in chronic infection or autoimmune disorders, delayed activation of reticular cells can alter lymph node structure and either inhibit or intensify immune responses. Mueller and Germain (2015) found that excessive signaling from reticular cells contributes to immune dysregulation, leading to disorders in the body such as fibrosis. Conversely, it has been shown that controlled activation can actually enhance immune protection. Recent research also links fibroblastic reticular cells to anti-tumor immunity. In a 2025 Cell study, Onder et al. discovered that reticular cells located near tumors in lung cancer generate unique environments that allow cytotoxic T cells to infiltrate deeper into the cancer.
=== Pharmacodynamics === Gabapentin is a ligand of the α2δ calcium channel subunit. The α2δ-1 protein is coded by the CACNA2D1 gene. α2δ was first described as an auxiliary protein connected to the main α1 subunit (the channel-forming protein) of high voltage activated voltage-dependent calcium channels (L-type, N-type, P/Q type, and R-type). The same α2δ protein has more recently been shown to interact directly with some NMDA-type and AMPA-type glutamate receptors at presynaptic sites and also with thrombospondin (an extracellular matrix protein secreted by astroglial cells). Gabapentin is not a direct calcium channel blocker: it exerts its actions by disrupting the regulatory function of α2δ and its interactions with other proteins. Gabapentin reduces delivery of intracellular calcium channels to the cell membrane, reduces the activation of the channels by the α2δ subunit, decreases signaling to lead to neurotransmitters release, and disrupts interactions of α2δ with voltage gated calcium channels but also with NMDA receptors, neurexins, and thrombospondin. These proteins are found as mutually interacting parts of the presynaptic active zone, where numerous protein molecules interact with each other to enable and to regulate the release of neurotransmitters from presynaptic vesicles into the synaptic space. Out of the four known isoforms of α2δ protein, gabapentin binds with similar high affinity to two: α2δ-1 and α2δ-2. All of the pharmacological properties of gabapentin tested to date are explained by its binding to just one isoform – α2δ-1.
=== Lyrics and themes === Since their first album, they have tackled subjects viewed from a nihilistic and cynical angle: alcohol abuse, drug use, suicidal thoughts, mental illness, alienation, loneliness, addiction, suicide, and death. They have addressed topics they have directly observed, as well as others drawn from tangible reality, or from their loved ones' experiences. The lyrics deal predominantly with personal subjects, as Toufouti has not been inclined to "talk about things that are a little too made up". They preferred to stick to topics they knew well, as they considered this approach enabled them to remain "authentic". To assert their "own identity" through their place of origin, namely Paris, the group incorporated "typical French references" as well as artwork featuring the Apaches, who were gangs of violent Parisian thugs from the 20th-century criminal underworld. The cover artwork of This Is Not Supposed To Be Positive depicts French executioner Anatole Deibler. The song title in French, "Le rouge pour le sang, le bleu pour la grâce" (lit. 'Red for Blood, Blue for Grace'), refers to the colour codes used by Deibler in his notebook, which listed the names of those condemned to the guillotine with a red cross circled in black and those pardoned with a blue cross. The French title of the instrumental song, "Les enfants des monstres pleurent leur désespoir" (lit. 'The Monsters' Children Weep Their Despair'), appearing on that album, originates from a documentary about [Gérard] Depardieu and his son's death.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.